Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 12/20 | 0.84 |
| ▸ | HTR1B | P28222 | 12/20 | 0.84 |
| ▸ | HTR1A | P08908 | 2/20 | 0.84 |
| ▸ | APP | P05067 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | HTR1F | P30939 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naratriptan SCHEMBL68753 | 0.92 | HTR1D (1.00) | HTR1DHTR1BHTR1AAPPCYP1A2 | |
| Naratriptan SCHEMBL29403931 | 0.92 | HTR1D (1.00) | HTR1DHTR1BHTR1AAPPCYP1A2 | |
| Naratriptan SCHEMBL28587084 | 0.91 | HTR1D (0.98) | HTR1DHTR1BHTR1AAPPCYP1A2 | |
| Naratriptan SCHEMBL41527 | 0.91 | HTR1D (0.98) | HTR1DHTR1BHTR1AAPPCYP1A2 | |
| Naratriptan SCHEMBL12803311 | 0.91 | HTR1D (0.98) | HTR1DHTR1BHTR1AAPPCYP1A2 | |
| Naratriptan SCHEMBL30903899 | 0.91 | HTR1D (0.98) | HTR1DHTR1BHTR1AAPPCYP1A2 | |
| Naratriptan SCHEMBL41528 | 0.90 | HTR1D (0.96) | HTR1DHTR1BHTR1AAPPCYP1A2 | |
| SCHEMBL2739044 | 0.89 | HTR1D (0.67) | HTR1DHTR1BHTR1AAPPCYP1A2 | |
| SCHEMBL9272206 | 0.85 | HTR1D (0.88) | HTR1DHTR1BHTR1AAPPCYP1A2 | |
| Hydrochloric Acid SCHEMBL9274904 | 0.85 | HTR1D (0.86) | HTR1DHTR1BHTR1AAPPCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802596-B2 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2014-08-12 | — | — | US | disclosed |
| US-8232265-B2 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232265-B2 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-07-31 | — | — | US | disclosed |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2007-04-26 | — | — | US | disclosed |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | SLC5A6, PNLIP, IPMK | HTR1D 3466/4885HTR1B 2183/4885HTR1A 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.